Pacira Surges 66.8% in Six Months: How Should You Play the Stock?

Shares of Pacira BioSciences (PCRX) have surged 66.8% in the past six months against the industry’s decline of 8.7%.  The stock has also outperformed the sector and the S&P 500 index during this timeframe.Strong quarterly results, consistent growth in sales of lead drug Exparel and encouraging pipeline progress have boosted investor sentiment.PCRX Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchExparel’s Performance Fuels PCRX GrowthExparel, Pacira’s flagship pain-management pro ...